Search results for "TLR7"

showing 10 items of 34 documents

Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation

2016

Dendritic cells (DCs) have been implicated in the pathogenesis of psoriasis but the roles for specific DC subsets are not well defined. Here we show that DCs are required for psoriasis-like changes in mouse skin induced by the local injection of IL-23. However, Flt3L-dependent DCs and resident Langerhans cells are dispensable for the inflammation. In epidermis and dermis, the critical DCs are TNF-producing and IL-1β-producing monocyte-derived DCs, including a population of inflammatory Langerhans cells. Depleting Ly6Chi blood monocytes reduces DC accumulation and the skin changes induced either by injecting IL-23 or by application of the TLR7 agonist imiquimod. Moreover, we find that IL-23-…

0301 basic medicineSciencePopulationGeneral Physics and Astronomychemical and pharmacologic phenomenaInflammationInterleukin-23ArticleMonocytesGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineMajor Histocompatibility ComplexMice03 medical and health sciencesAdjuvants ImmunologicPsoriasismedicineInterleukin 23AnimalsHumansPsoriasiseducationSkinInflammationMice Knockouteducation.field_of_studyImiquimodMultidisciplinaryFollicular dendritic cellsbusiness.industryMonocyteQMembrane Proteinshemic and immune systemsDendritic CellsGeneral ChemistryTLR7medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureGene Expression RegulationLangerhans CellsImmunologyAminoquinolinesDrug Eruptionsmedicine.symptombusinessNature Communications
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection

2017

Abstract Background Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses. Objective Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination …

0301 basic medicineSkin NeoplasmsT cellImiquimodDermatologyLymphocytic ChoriomeningitisAdministration CutaneousBiochemistryEpitopeMajor Histocompatibility ComplexEpitopesMice03 medical and health sciences0302 clinical medicineImmune systemCell MovementAnimalsHumansLymphocytic choriomeningitis virusMedicineCytotoxic T cellMolecular BiologySkinMice KnockoutImiquimodMembrane Glycoproteinsbusiness.industryVaccinationTLR7Flow CytometryMice Inbred C57BLDisease Models AnimalCTL*030104 developmental biologymedicine.anatomical_structureToll-Like Receptor 7Langerhans Cells030220 oncology & carcinogenesisMyeloid Differentiation Factor 88ImmunologyAminoquinolinesEmulsionsbusinessCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugJournal of Dermatological Science
researchProduct

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

2019

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8(+) T cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsImmunologytype i interferonlcsh:RC254-282Proinflammatory cytokinetlr7 ligand03 medical and health sciences0302 clinical medicineImmune systemInterferonmedicineImmunology and AllergyCytotoxic T cellOriginal ResearchToll-like receptorcancer immunotherapybusiness.industryTLR7Acquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinesslcsh:RC581-607CD8medicine.drugOncoImmunology
researchProduct

RNA Modifications Modulate Activation of Innate Toll-Like Receptors

2019

Self/foreign discrimination by the innate immune system depends on receptors that identify molecular patterns as associated to pathogens. Among others, this group includes endosomal Toll-like receptors, among which Toll-like receptors (TLR) 3, 7, 8, and 13 recognize and discriminate mammalian from microbial, potentially pathogen-associated, RNA. One of the discriminatory principles is the recognition of endogenous RNA modifications. Previous work has identified a couple of RNA modifications that impede activation of TLR signaling when incorporated in synthetic RNA molecules. Of note, work that is more recent has now shown that RNA modifications in their naturally occurring context can have …

0301 basic medicinelcsh:QH426-470EndosomeContext (language use)ReviewBiology03 medical and health sciences0302 clinical medicineRNA modificationsGeneticsAnimalsHumansGenetics(clinical)RNA Processing Post-TranscriptionalReceptorGeneinnate immunityGenetics (clinical)Innate immune systemRNATLR7Immunity InnateCell biologyToll-like receptorslcsh:Genetics030104 developmental biologyTransfer RNAmethylation030215 immunologyGenes
researchProduct

2'-O-methylation within prokaryotic and eukaryotic tRNA inhibits innate immune activation by endosomal Toll-like receptors but does not affect recogn…

2019

Bacterial RNA has emerged as an important activator of innate immune responses by stimulating Toll-like receptors TLR7 and TLR8 in humans. Guanosine 2′-O-methylation at position 18 (Gm18) in bacterial tRNA was shown to antagonize tRNA-induced TLR7/8 activation, suggesting a potential role of Gm18 as an immune escape mechanism. This modification also occurs in eukaryotic tRNA, yet a physiological immune function remained to be tested. We therefore set out to investigate the immune modulatory role of Gm18 in both prokaryotic and eukaryotic microorganisms, Escherichia coli and Saccharomyces cerevisiae, and in human cells. Using RiboMethSeq analysis we show that mutation of trmH in E. coli, trm…

0303 health sciencesTRNA modificationInnate immune system030302 biochemistry & molecular biologyRNA[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyTLR7BiologyTLR8[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyCell biology03 medical and health sciencesImmune system[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Transfer RNAGene expression[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Molecular BiologyComputingMilieux_MISCELLANEOUS030304 developmental biology
researchProduct

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune res…

2021

Significance Vaccines profit from the addition of adjuvants to better and more specifically initiate, amplify, and shape immune responses. Although the number of adjuvant candidates has steadily increased, peaking in the current SARS-CoV-2 pandemic, little is known about their inherent mode of action. Using human blood immune cells, we established a multilayer method to systematically assess the adjuvants’ effects on innate and adaptive immune cells. By employing a multiplex analysis with cells from 30 different donors, we determined important patterns of adjuvant function. Moreover, we demonstrate correlates of an antiviral immune response using a Toll-like receptor 7/8 ligand adjuvant and…

AdultMaleAdolescentT-LymphocytesMonophosphoryl Lipid ALipid Achemistry.chemical_compoundImmunology and InflammationImmune systemAdjuvants ImmunologicInterferonTLRmedicineHumansprimary human cellsAgedImmunity CellularToll-like receptorMultidisciplinarySARS-CoV-2ChemistryToll-Like ReceptorsImidazolesCOVID-19Dendritic CellsTLR7biochemical phenomena metabolism and nutritionBiological SciencesMiddle AgedCOVID-19 ; TLR ; primary human cells ; adjuvants ; mRNA vaccines420Cell biologymRNA vaccinesLipid AadjuvantsTLR4[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleResiquimodmedicine.drugProceedings of the National Academy of Sciences
researchProduct

Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms

2016

Abstract Mechanisms of antiviral host defense are important for survival and evolutionarily optimized for high sensitivity and potency. Intending to harvest the multitude of highly specialized and intertwined pathogen immune defense programs for cancer immunotherapy, we simulated a systemic pathogen intrusion into the blood stream by intravenous injection of lipid-formulated, tumor antigen-encoding mRNA nanoparticles. These RNA-lipoplexes (RNA-LPX) were directed to various lymphoid tissues, including the spleen, lymph nodes and bone marrow, which provide the ideal microenvironment for efficient priming and amplification of T cell responses. Solely the RNA-to-lipid ratio was discovered to de…

Cancer ResearchInnate immune systemmedicine.medical_treatmentT cellImmunologyTLR7Biologymedicine.anatomical_structureCancer immunotherapyAntigenImmunologymedicineCytotoxic T cellAntigen-presenting cellCD8Cancer Immunology Research
researchProduct

An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration

2011

Activation of innate immune receptors by host-derived factors exacerbates CNS damage, but the identity of these factors remains elusive. We uncovered an unconventional role for the microRNA let-7, a highly abundant regulator of gene expression in the CNS, in which extracellular let-7 activates the RNA-sensing Toll-like receptor (TLR) 7 and induces neurodegeneration through neuronal TLR7. Cerebrospinal fluid (CSF) from individuals with Alzheimer’s disease contains increased amounts of let-7b, and extracellular introduction of let-7b into the CSF of wild-type mice by intrathecal injection resulted in neurodegeneration. Mice lacking TLR7 were resistant to this neurodegenerative effect, but thi…

Cell signalingApoptosisElectrophoretic Mobility Shift AssayBiologyReal-Time Polymerase Chain ReactionMiceAlzheimer DiseasemicroRNAExtracellularmedicineAnimalsHumansReceptorIn Situ HybridizationMice KnockoutNeuronsToll-like receptorMembrane GlycoproteinsMicroscopy ConfocalInnate immune systemGeneral NeuroscienceNeurodegenerationBrainvirus diseasesTLR7medicine.diseaseImmunohistochemistryMice Inbred C57BLMicroRNAsHEK293 CellsToll-Like Receptor 7Nerve DegenerationCancer researchSignal TransductionNature Neuroscience
researchProduct

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.

2005

Abstract CTL are important in combating cancer and viruses. Therefore, triggering the complete potential of CTL effector functions by new vaccination strategies will not only improve prophylaxis of tumor or virus-related diseases, but also open opportunities for effective therapeutic immunizations. Using transcutaneous immunization, we show that epicutaneous (e.c.)4 application of an ointment containing a CTL epitope and the TLR7 ligand imiquimod is highly effective in activating T cells in mice using TCR-transgenic CTL or in wild-type mice. Transcutaneous immunization-activated CTL mount a full-blown immune response against the target epitope characterized by proliferation, cytolytic activ…

Cytotoxicity ImmunologicAdoptive cell transferImmunologyReceptors Antigen T-CellPriming (immunology)Epitopes T-Lymphocytechemical and pharmacologic phenomenaImiquimodMice TransgenicAdministration CutaneousLymphocyte ActivationResting Phase Cell CycleEpitopeMiceImmune systemmedicineImmunology and AllergyAnimalsCells CulturedMice KnockoutImiquimodbusiness.industryTLR7VirologyAdoptive TransferVaccinationMice Inbred C57BLCTL*Protein TransportImmunologyVaccines SubunitAminoquinolinesLymph NodesbusinessSpleenmedicine.drugT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct